AVAH

Aveanna Healthcare Holdings Inc.

Fundamental data last updated:October 28, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Care Facilities

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

11/12/2026

Business Summary

Aveanna Healthcare Holdings Inc. operates as a diverse platform for home-based care services throughout the United States. The company delivers a range of critical offerings, including private duty nursing (PDN), adult home health and hospice care, in-home pediatric therapy, and enteral nutrition services. Its patient-centered approach allows individuals to receive essential medical care within their own homes, effectively reducing the need for costly institutional settings such as hospitals. The company's operations are structured into three key segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment provides specialized private duty nursing, which includes skilled nursing care for medically fragile children at home, nursing support in school environments, and services at pediatric day healthcare centers. This segment also offers employer-of-record support, personal care services, and pediatric therapy (physical, occupational, and speech) provided both in clinics and patients' residences. The HHH segment focuses on home health services, encompassing in-home skilled nursing, physical, occupational, and speech therapy, as well as medical social work and aide assistance. Furthermore, it delivers hospice services, offering compassionate care to patients and their families when life-limiting illnesses no longer respond to curative treatments. The MS segment supplies enteral nutrition products and other vital medical supplies to adults and children, distributed on either a scheduled or as-needed basis. Founded in 2016, Aveanna Healthcare Holdings Inc. is headquartered in Atlanta, Georgia.

 


VALUATION

P/E

9.99

Market Cap ($M USD)

$2.89B

Forward P/E

16.08

PEG

0.24

PRICE TO SALES

1.11

PRICE TO BOOK

10.05

EV / EBITDA

13.96

5-Year Average P/E

Free Cash Flow Yield

5.73%

DCF Value

$-9.96

Graham Number

$6.12

Price to FCF

17.46

EV to FCF

25.95

Earnings Yield

9.51%

FCF Yield

5.73%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.26

Next Year EPS Growth Estimate

$0.82

Next Year Revenue Growth Estimate

$2.69B

Return on Equity (ROE)

150.20%

FREE CASH FLOW

Operating Margin

11.12%

Debt-to-Equity

5.24

Piotroski F-Score

5

Altman Z-Score

1.96

Return on Invested Capital (ROIC)

15.32%

Current Ratio

1.16

Quick Ratio

1.16

Net Debt to EBITDA

4.57

Interest Coverage

2.32

Gross Profit margin

31.95%

FCF PER SHARE

$0.76

REVENUE PER SHARE

$11.95

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Aveanna Healthcare Holdings Inc., as its snapshot price traded below its DCF value, suggesting potential undervaluation. However, the Graham Number also indicates a lower intrinsic value, raising questions about its true worth. The Forward P/E of 9.04 and an Earnings Yield of 16.40% suggest a potentially attractive entry point for value investors, yet the Altman Z-score of 1.37 signals financial distress, hinting at underlying risks. The company’s financial health is a mixed bag, with impressive earnings yield overshadowed by structural vulnerabilities.

AI Exposure / Tech Reliance

Operating in the healthcare sector, Aveanna is well-positioned to leverage AI advancements in patient care and operational efficiency. The medical care facilities industry is ripe for tech integration, potentially enhancing service delivery and cost management. However, the company must strategically invest in tech to stay competitive and relevant.

The Bull Case

For the discerning value investor, Aveanna offers compelling reasons to buy. With a robust ROIC of 16.57%, the company demonstrates strong capital efficiency, translating into real-world pricing power. The FCF Yield of 8.58% and a Piotroski F-Score of 5 indicate solid financial health and operational efficiency. Its operating margin of 10.91% underscores effective cost management, making it an attractive proposition for those seeking growth at a reasonable price.

The Bear Case

Despite some strengths, Aveanna faces significant structural risks. The Price/Book ratio of 7.05 and Price/Sales ratio of 0.60 suggest overvaluation relative to its book value and sales. The company's high Debt/Equity ratio of 6.91 raises alarms about its leverage and financial stability. Additionally, its proximity to the 52-week low indicates potential market skepticism about its future prospects.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$14.38

Institutional Ownership %

1-Year Beta

1.95

Insider Buying % (6 Mo)

Distance to 52-Week High

10.94%

Distance to 52-Week Low

55.28%

EARNINGS SURPRISE %

30.72%

50-DAY SMA

$13.07

200-DAY SMA

$9.12

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.